S 3716119th CongressIn Committee
RARE Act
Standard Summary
Balanced plain-English summary
The RARE Act changes how orphan drug exclusivity is applied under the Federal Food, Drug, and Cosmetic Act. It limits seven-year exclusivity to the same approved use or indication within a rare disease or condition rather than the entire rare disease or condition, and applies the change to previously designated drugs.
Key Points
- 1Amends orphan drug exclusivity provisions in the Federal Food, Drug, and Cosmetic Act.
- 2Narrows exclusivity from the same rare disease or condition to the same approved use or indication.
- 3Defines “approved use or indication” by reference to FDA approval or licensure.
- 4Applies the amendments regardless of when a drug was designated or approved.
Impact Areas
Rare disease patientsPharmaceutical manufacturersFDAHealth insurers and payers
Generated by deepseek/deepseek-v4.1-flash-1017Nov 18, 2026